These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 26424421)

  • 21. Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone.
    Sliwa JK; Bossie CA; Ma YW; Alphs L
    Schizophr Res; 2011 Oct; 132(1):28-34. PubMed ID: 21775106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study.
    Davidson M; Emsley R; Kramer M; Ford L; Pan G; Lim P; Eerdekens M
    Schizophr Res; 2007 Jul; 93(1-3):117-30. PubMed ID: 17466492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid onset of treatment effects on psychosis, depression, and mania in patients with acute exacerbation of schizoaffective disorder following treatment with oral extended-release paliperidone.
    Fu DJ; Turkoz I; Bossie CA; Patel H; Alphs L
    J Affect Disord; 2016 Mar; 193():381-90. PubMed ID: 26802315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder.
    Fu DJ; Turkoz I; Walling D; Lindenmayer JP; Schooler NR; Alphs L
    Schizophr Res; 2018 Feb; 192():185-193. PubMed ID: 28454922
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetic drug evaluation of paliperidone in the treatment of schizoaffective disorder.
    Macaluso M; Oliver H; Sohail Z
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):871-879. PubMed ID: 28675307
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Cost-effectiveness analysis of aripiprazole once-monthly versus paliperidone palmitate once-monthly in the treatment of schizophrenia in France].
    Gozlan G; Lecardeur L; Monfort AS; Doz M; Ortiz I; Larroumets P; Lafuma A
    Encephale; 2018 Dec; 44(6):496-503. PubMed ID: 30482480
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers.
    Canuso CM; Schooler N; Carothers J; Turkoz I; Kosik-Gonzalez C; Bossie CA; Walling D; Lindenmayer JP
    J Clin Psychopharmacol; 2010 Oct; 30(5):487-95. PubMed ID: 20814330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Healthcare utilization and costs of Veterans Health Administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics.
    Baser O; Xie L; Pesa J; Durkin M
    J Med Econ; 2015 May; 18(5):357-65. PubMed ID: 25525771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and tolerability of paliperidone ER in patients with unsatisfactorily controlled schizophrenia by other antipsychotics: a flexible-dose approach.
    Mauri M; Mauri MC; Adami M; Reggiardo G; Giulio C
    Int Clin Psychopharmacol; 2015 Nov; 30(6):329-37. PubMed ID: 26230269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder.
    Fu DJ; Turkoz I; Simonson RB; Walling DP; Schooler NR; Lindenmayer JP; Canuso CM; Alphs L
    J Clin Psychiatry; 2015 Mar; 76(3):253-62. PubMed ID: 25562685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paliperidone Long-Acting Plasma Level Monitoring and a New Method of Evaluation of Clinical Stability.
    Mauri MC; Paletta S; Di Pace C; Reggiori A; Rovera C; Fiorentini A; Altamura CA
    Pharmacopsychiatry; 2017 Jul; 50(4):145-151. PubMed ID: 28278537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genome-wide association study of paliperidone efficacy.
    Li Q; Wineinger NE; Fu DJ; Libiger O; Alphs L; Savitz A; Gopal S; Cohen N; Schork NJ
    Pharmacogenet Genomics; 2017 Jan; 27(1):7-18. PubMed ID: 27846195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world adherence and economic outcomes associated with paliperidone palmitate versus oral atypical antipsychotics in schizophrenia patients with substance-related disorders using Medicaid benefits.
    Joshi K; Lafeuille MH; Kamstra R; Tiggelaar S; Lefebvre P; Kim E; Yue Y; Tandon N
    J Comp Eff Res; 2018 Feb; 7(2):121-133. PubMed ID: 28809128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of acute schizophrenia with paliperidone ER: predictors for treatment response and benzodiazepine use.
    Heres S; Don L; Herceg M; Bidzan L; Blanc M; Siracusano A; Maciulis V; Lahaye M; Schreiner A
    Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jan; 48():207-12. PubMed ID: 24096139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early predictors of a clinical response at 8 weeks in patients with first-episode psychosis treated with paliperidone ER.
    Chung YC; Cui Y; Kim MG; Kim YJ; Lee KH; Chae SW
    J Psychopharmacol; 2016 Aug; 30(8):810-8. PubMed ID: 27334812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse.
    Lefebvre P; Muser E; Joshi K; DerSarkissian M; Bhak RH; Duh MS; Shiner B; Young-Xu Y
    Clin Ther; 2017 Jul; 39(7):1380-1395.e4. PubMed ID: 28641996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cost-effectiveness of paliperidone extended release in Spain.
    Treur M; Baca E; Bobes J; Cañas F; Salvador L; Gonzalez B; Heeg B
    J Med Econ; 2012; 15 Suppl 1():26-34. PubMed ID: 23016569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictive factors of overall functioning improvement in patients with chronic schizophrenia and schizoaffective disorder treated with paliperidone palmitate and aripiprazole monohydrate.
    Girardi P; Del Casale A; Rapinesi C; Kotzalidis GD; Splendori F; Verzura C; Trovini G; Sorice S; Carrus D; Mancinelli I; Comparelli A; De Filippis S; Francomano A; Ballerini A; Marcellusi A; Mennini FS; Ducci G; Sani G; Pompili M; Brugnoli R
    Hum Psychopharmacol; 2018 May; 33(3):e2658. PubMed ID: 29766576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Health Care Utilization and Treatment Persistence Associated with Oral Paliperidone and Lurasidone in Schizophrenia Treatment.
    Jiang Y; Ni W
    J Manag Care Spec Pharm; 2015 Sep; 21(9):780-92. PubMed ID: 26308225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.